The appointment ends a prolonged interim leadership period and provides a clear succession plan. Willard's e-commerce experience (StewMac, Casper) aligns with PetMeds' direct-to-consumer pet pharmacy model. Monitor the next quarterly report for revenue and profitability trends to assess whether the turnaround strategy is gaining traction. The $4.00 per-share Change of Control bonus threshold suggests the Board may have considered a potential sale scenario at that valuation.
Price Chart
Executive Summary
PetMed Express (PETS) appointed Jeff Willard as permanent CEO/President effective September 28, 2026, replacing interim CEO Leslie C.G. Campbell who is retiring. The company also named Justin Mennen as independent Board Chair. Willard receives a $550K base salary, $120K signing bonus, $50K relocation, and equity grants of 250K restricted shares plus up to 250K performance stock units. This ends a 13-month interim CEO period and provides leadership stability, but the company faces a turnaround challenge with no financial data disclosed.
Key Facts
- Jeff Willard appointed CEO/President effective September 28, 2026, succeeding interim CEO Leslie C.G. Campbell who served since August 2025
- Willard receives $550,000 annual base salary, $120,000 signing bonus, $50,000 relocation allowance
- Initial equity grant: 250,000 restricted shares (3-year vesting) + up to 250,000 performance stock units (3-year TSR vs S&P 600 Specialty Retail Index)
- Annual equity target of $750,000 beginning after first anniversary, capped at 1% of outstanding shares
- Justin Mennen appointed independent Board Chair; Campbell remains as Strategic Advisor for 60 days post-transition
- Willard's employment agreement includes 12-month severance (24-month post-Change of Control) and a $1.5M transaction bonus if Change of Control occurs before 24-month anniversary with per-share consideration ≥ $4.00
Financial Impact
New CEO compensation package totals approximately $720K in first-year cash (salary + signing bonus + relocation) plus 500K shares of restricted stock and up to 500K performance stock units. No financial results or guidance were disclosed in this filing
Risk Factors
- No financial results or guidance were provided in this filing; the company has been in a turnaround phase under interim management since August 2025
- Willard's prior CEO role at StewMac (private) and Casper (private post-take-private) provides limited public-company CEO track record for investors to evaluate
- The $1.5M transaction bonus tied to a $4.00/share Change of Control threshold may signal the Board's internal valuation floor for a potential sale scenario
- Clawback provisions on signing bonus ($120K) and relocation ($50K) within first year indicate retention risk for the first year
- No relatedTickers: no counterparty tickers appear in the document text
- No drugNames: not a biotech/pharma filing
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001040130-26-000045 |
| Document: pets-20260917.htm | 0001040130-26-000045 |
| Document: pets-ceoandboardchairtrans.htm | 0001040130-26-000045 |
| Document: 0001040130-26-000045-index-headers.html | 0001040130-26-000045 |
| Document: 0001040130-26-000045-index.html | 0001040130-26-000045 |
| Document: 0001040130-26-000045.txt | 0001040130-26-000045 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | Press Release | $1.32 $1.26 | ▼ −4.55% | ▼ −4.97% | $1.16 (−12.12%) |
Sep 21, 2026 5w ago | 8-K | $1.60 $1.41 | ▼ −12.19% | ▼ −11.17% | $1.16 (−27.50%) |
Sep 17, 2026 5w ago | 8-K | $1.62 $1.56 | ▼ −4.01% | ▼ −4.61% | $1.16 (−28.40%) |
Sep 17, 2026 5w ago | Press Release | $1.62 $1.56 | ▼ −3.70% | ▼ −4.55% | $1.16 (−28.40%) |
Jun 26, 2026 17w ago | 8-K | $1.82 $1.96 | ▲ +7.69% | ▲ +6.30% | $1.16 (−36.26%) |
Jun 25, 2026 17w ago | DEFA14A | $1.76 $1.98 | ▲ +12.50% | ▲ +10.33% | $1.16 (−34.09%) |
Jun 2, 2026 20w ago | 8-K | $1.78 $1.72 | ▲ +3.37% | ▼ −0.45% | $1.16 (+34.83%) |
Jun 2, 2026 20w ago | Press Release | $1.78 $1.72 | ▲ +3.37% | ▼ −0.45% | $1.16 (+34.83%) |
May 29, 2026 21w ago | Press Release | $2.17 $1.68 | ▼ −22.58% | ▼ −20.06% | $1.16 (−46.54%) |
Apr 22, 2026 26w ago | Press Release | $2.23 $2.26 | ▲ +1.35% | ▼ −0.13% | $1.16 (−47.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers